ID   KCRB_HUMAN              Reviewed;         381 AA.
AC   P12277; A8K236; B2R5R4; Q2LE07; Q6FG40; Q9UC66;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 1.
DT   12-APR-2017, entry version 182.
DE   RecName: Full=Creatine kinase B-type;
DE            EC=2.7.3.2;
DE   AltName: Full=B-CK;
DE   AltName: Full=Creatine kinase B chain;
GN   Name=CKB; Synonyms=CKBB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3034271; DOI=10.1016/0006-291X(87)91427-6;
RA   Villarreal-Levy G., Ma T.S., Kerner S.A., Roberts R., Perryman M.B.;
RT   "Human creatine kinase: isolation and sequence analysis of cDNA clones
RT   for the B subunit, development of subunit specific probes and
RT   determination of gene copy number.";
RL   Biochem. Biophys. Res. Commun. 144:1116-1127(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3692484; DOI=10.1016/0888-7543(87)90004-8;
RA   Mariman E.C.M., Broers C.A.M., Claesen C.A.A., Tesser G.I.,
RA   Wieringa B.;
RT   "Structure and expression of the human creatine kinase B gene.";
RL   Genomics 1:126-137(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2883200; DOI=10.1172/JCI112969;
RA   Kaye F.J., McBride O.W., Battey J.F., Gazder A.F., Sausville E.A.;
RT   "Human creatine kinase-B complementary DNA. Nucleotide sequence, gene
RT   expression in lung cancer, and chromosomal assignment to two distinct
RT   loci.";
RL   J. Clin. Invest. 79:1412-1420(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Brain;
RX   PubMed=2771648; DOI=10.1093/nar/17.15.6385;
RA   Mariman E.C.M., Schepens J.T.G., Wieringa B.;
RT   "Complete nucleotide sequence of the human creatine kinase B gene.";
RL   Nucleic Acids Res. 17:6385-6385(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum, and Subthalamic nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-177 AND LEU-309.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Eye, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-97.
RX   PubMed=2828370;
RA   Daouk G.H., Kaddurah-Daouk R., Putney S., Kingston R., Schimmel P.;
RT   "Isolation of a functional human gene for brain creatine kinase.";
RL   J. Biol. Chem. 263:2442-2446(1988).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-22.
RC   TISSUE=Eye;
RX   PubMed=7637327;
RA   Kliffen M., de Jong P.T.V.M., Luider T.M.;
RT   "Protein analysis of human maculae in relation to age-related
RT   maculopathy.";
RL   Lab. Invest. 73:267-272(1995).
RN   [12]
RP   PROTEIN SEQUENCE OF 2-11; 33-43; 157-172; 224-236; 253-265; 308-314
RP   AND 342-366, CLEAVAGE OF INITIATOR METHIONINE, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Heiserich L., Gottlieb E.;
RL   Submitted (MAR-2008) to UniProtKB.
RN   [13]
RP   PROTEIN SEQUENCE OF 33-43; 87-96; 108-130; 157-172; 224-236; 253-265;
RP   320-341 AND 359-381, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [14]
RP   MUTAGENESIS OF CYS-283; ARG-292 AND ASP-340.
RX   PubMed=8186255;
RA   Lin L., Perryman M.B., Friedman D., Roberts R., Ma T.S.;
RT   "Determination of the catalytic site of creatine kinase by site-
RT   directed mutagenesis.";
RL   Biochim. Biophys. Acta 1206:97-104(1994).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-35 AND SER-199, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4 AND THR-35, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH ADP AND
RP   CREATINE, ATP-BINDING SITES, AND SUBSTRATE-BINDING SITES.
RX   PubMed=18977227; DOI=10.1016/j.febslet.2008.10.039;
RA   Bong S.M., Moon J.H., Nam K.H., Lee K.S., Chi Y.M., Hwang K.Y.;
RT   "Structural studies of human brain-type creatine kinase complexed with
RT   the ADP-Mg2+-NO3- -creatine transition-state analogue complex.";
RL   FEBS Lett. 582:3959-3965(2008).
CC   -!- FUNCTION: Reversibly catalyzes the transfer of phosphate between
CC       ATP and various phosphogens (e.g. creatine phosphate). Creatine
CC       kinase isoenzymes play a central role in energy transduction in
CC       tissues with large, fluctuating energy demands, such as skeletal
CC       muscle, heart, brain and spermatozoa.
CC   -!- CATALYTIC ACTIVITY: ATP + creatine = ADP + phosphocreatine.
CC       {ECO:0000255|PROSITE-ProRule:PRU10029}.
CC   -!- SUBUNIT: Dimer of identical or non-identical chains. With MM being
CC       the major form in skeletal muscle and myocardium, MB existing in
CC       myocardium, and BB existing in many tissues, especially brain.
CC       {ECO:0000269|PubMed:18977227}.
CC   -!- INTERACTION:
CC       Q03463:- (xeno); NbExp=3; IntAct=EBI-357706, EBI-9081620;
CC       Q96DX5:ASB9; NbExp=8; IntAct=EBI-357706, EBI-745641;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- SIMILARITY: Belongs to the ATP:guanido phosphotransferase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00842, ECO:0000255|PROSITE-
CC       ProRule:PRU00843}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ckb/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Creatine kinase entry;
CC       URL="https://en.wikipedia.org/wiki/Creatine_kinase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16451; AAA76851.1; -; mRNA.
DR   EMBL; M21243; AAC31758.1; -; Genomic_DNA.
DR   EMBL; M21237; AAC31758.1; JOINED; Genomic_DNA.
DR   EMBL; M21238; AAC31758.1; JOINED; Genomic_DNA.
DR   EMBL; M21239; AAC31758.1; JOINED; Genomic_DNA.
DR   EMBL; M21240; AAC31758.1; JOINED; Genomic_DNA.
DR   EMBL; M21241; AAC31758.1; JOINED; Genomic_DNA.
DR   EMBL; M21242; AAC31758.1; JOINED; Genomic_DNA.
DR   EMBL; L47647; AAA76852.1; -; mRNA.
DR   EMBL; M16364; AAA76850.1; -; mRNA.
DR   EMBL; X15334; CAA33389.1; -; Genomic_DNA.
DR   EMBL; AK290101; BAF82790.1; -; mRNA.
DR   EMBL; AK312282; BAG35211.1; -; mRNA.
DR   EMBL; CR542268; CAG47064.1; -; mRNA.
DR   EMBL; DQ333313; ABC67465.1; -; Genomic_DNA.
DR   EMBL; CH471061; EAW81822.1; -; Genomic_DNA.
DR   EMBL; BC001190; AAH01190.1; -; mRNA.
DR   EMBL; BC004914; AAH04914.1; -; mRNA.
DR   EMBL; BC008323; AAH08323.1; -; mRNA.
DR   EMBL; BC010002; AAH10002.1; -; mRNA.
DR   EMBL; BC019259; AAH19259.1; -; mRNA.
DR   EMBL; BC019281; AAH19281.1; -; mRNA.
DR   EMBL; M22356; AAA52024.1; -; Genomic_DNA.
DR   EMBL; M22355; AAA52024.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS9981.1; -.
DR   PIR; S15935; KIHUCB.
DR   RefSeq; NP_001814.2; NM_001823.4.
DR   UniGene; Hs.173724; -.
DR   PDB; 3B6R; X-ray; 2.00 A; A/B=1-381.
DR   PDB; 3DRB; X-ray; 2.00 A; A/B=1-381.
DR   PDB; 3DRE; X-ray; 2.20 A; A/B=1-381.
DR   PDBsum; 3B6R; -.
DR   PDBsum; 3DRB; -.
DR   PDBsum; 3DRE; -.
DR   ProteinModelPortal; P12277; -.
DR   SMR; P12277; -.
DR   BioGrid; 107572; 78.
DR   DIP; DIP-52968N; -.
DR   IntAct; P12277; 40.
DR   MINT; MINT-1484821; -.
DR   STRING; 9606.ENSP00000299198; -.
DR   ChEMBL; CHEMBL6049; -.
DR   DrugBank; DB00148; Creatine.
DR   iPTMnet; P12277; -.
DR   PhosphoSitePlus; P12277; -.
DR   BioMuta; CKB; -.
DR   DMDM; 125294; -.
DR   REPRODUCTION-2DPAGE; IPI00022977; -.
DR   REPRODUCTION-2DPAGE; P12277; -.
DR   UCD-2DPAGE; P12277; -.
DR   EPD; P12277; -.
DR   PaxDb; P12277; -.
DR   PeptideAtlas; P12277; -.
DR   PRIDE; P12277; -.
DR   TopDownProteomics; P12277; -.
DR   DNASU; 1152; -.
DR   Ensembl; ENST00000348956; ENSP00000299198; ENSG00000166165.
DR   GeneID; 1152; -.
DR   KEGG; hsa:1152; -.
DR   CTD; 1152; -.
DR   DisGeNET; 1152; -.
DR   GeneCards; CKB; -.
DR   HGNC; HGNC:1991; CKB.
DR   HPA; CAB047313; -.
DR   HPA; HPA001254; -.
DR   MIM; 123280; gene.
DR   neXtProt; NX_P12277; -.
DR   OpenTargets; ENSG00000166165; -.
DR   PharmGKB; PA26528; -.
DR   eggNOG; KOG3581; Eukaryota.
DR   eggNOG; COG3869; LUCA.
DR   GeneTree; ENSGT00550000074561; -.
DR   HOGENOM; HOG000232165; -.
DR   HOVERGEN; HBG001339; -.
DR   InParanoid; P12277; -.
DR   KO; K00933; -.
DR   OMA; RGHEFMW; -.
DR   OrthoDB; EOG091G0HZ0; -.
DR   PhylomeDB; P12277; -.
DR   TreeFam; TF314214; -.
DR   BioCyc; MetaCyc:HS09344-MONOMER; -.
DR   BRENDA; 2.7.3.2; 2681.
DR   Reactome; R-HSA-71288; Creatine metabolism.
DR   SABIO-RK; P12277; -.
DR   ChiTaRS; CKB; human.
DR   EvolutionaryTrace; P12277; -.
DR   GeneWiki; CKB_(gene); -.
DR   GenomeRNAi; 1152; -.
DR   PRO; PR:P12277; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000166165; -.
DR   CleanEx; HS_CKB; -.
DR   ExpressionAtlas; P12277; baseline and differential.
DR   Genevisible; P12277; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; ISS:AgBase.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004111; F:creatine kinase activity; ISS:AgBase.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0030644; P:cellular chloride ion homeostasis; IEA:Ensembl.
DR   GO; GO:0021549; P:cerebellum development; IEA:Ensembl.
DR   GO; GO:0006600; P:creatine metabolic process; TAS:Reactome.
DR   GO; GO:0021762; P:substantia nigra development; IEP:UniProtKB.
DR   Gene3D; 1.10.135.10; -; 1.
DR   Gene3D; 3.30.590.10; -; 1.
DR   InterPro; IPR000749; ATP-guanido_PTrfase.
DR   InterPro; IPR022415; ATP-guanido_PTrfase_AS.
DR   InterPro; IPR022414; ATP-guanido_PTrfase_cat.
DR   InterPro; IPR022413; ATP-guanido_PTrfase_N.
DR   InterPro; IPR014746; Gln_synth/guanido_kin_cat_dom.
DR   PANTHER; PTHR11547; PTHR11547; 1.
DR   Pfam; PF00217; ATP-gua_Ptrans; 1.
DR   Pfam; PF02807; ATP-gua_PtransN; 1.
DR   SUPFAM; SSF48034; SSF48034; 1.
DR   PROSITE; PS00112; PHOSPHAGEN_KINASE; 1.
DR   PROSITE; PS51510; PHOSPHAGEN_KINASE_C; 1.
DR   PROSITE; PS51509; PHOSPHAGEN_KINASE_N; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Kinase; Nitration; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:7637327,
FT                                ECO:0000269|Ref.12}.
FT   CHAIN         2    381       Creatine kinase B-type.
FT                                /FTId=PRO_0000211966.
FT   DOMAIN       11     98       Phosphagen kinase N-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00842}.
FT   DOMAIN      125    367       Phosphagen kinase C-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00843}.
FT   NP_BIND     128    132       ATP.
FT   NP_BIND     320    325       ATP.
FT   BINDING      72     72       Substrate; via amide nitrogen.
FT   BINDING     130    130       ATP.
FT   BINDING     132    132       ATP.
FT   BINDING     191    191       ATP.
FT   BINDING     232    232       Substrate.
FT   BINDING     236    236       ATP.
FT   BINDING     285    285       Substrate.
FT   BINDING     292    292       ATP.
FT   BINDING     320    320       ATP.
FT   BINDING     335    335       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00843}.
FT   MOD_RES       4      4       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      35     35       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     125    125       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q04447}.
FT   MOD_RES     199    199       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     269    269       Nitrated tyrosine.
FT                                {ECO:0000250|UniProtKB:Q04447}.
FT   MOD_RES     309    309       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P07335}.
FT   MOD_RES     322    322       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q04447}.
FT   VARIANT     177    177       K -> R (in dbSNP:rs36002620).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_025838.
FT   VARIANT     309    309       S -> L (in dbSNP:rs35156510).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_025839.
FT   VARIANT     360    360       L -> F (in dbSNP:rs12505).
FT                                /FTId=VAR_049674.
FT   MUTAGEN     283    283       C->S,Y: Complete loss of activity.
FT                                {ECO:0000269|PubMed:8186255}.
FT   MUTAGEN     292    292       R->H,L,Q: Complete loss of activity.
FT                                {ECO:0000269|PubMed:8186255}.
FT   MUTAGEN     292    292       R->K: 42% of wild-type activity.
FT                                {ECO:0000269|PubMed:8186255}.
FT   MUTAGEN     340    340       D->E: No change in activity.
FT                                {ECO:0000269|PubMed:8186255}.
FT   CONFLICT     41     42       EL -> DV (in Ref. 1; AAA76851).
FT                                {ECO:0000305}.
FT   CONFLICT     78     78       D -> G (in Ref. 3; AAA76850 and 10;
FT                                AAA52024). {ECO:0000305}.
FT   CONFLICT     98     99       GG -> RR (in Ref. 1; AAA76851).
FT                                {ECO:0000305}.
FT   CONFLICT    105    106       EH -> DD (in Ref. 1; AAA76851).
FT                                {ECO:0000305}.
FT   CONFLICT    130    130       R -> G (in Ref. 3; AAA76850).
FT                                {ECO:0000305}.
FT   CONFLICT    132    132       R -> A (in Ref. 1; AAA76851).
FT                                {ECO:0000305}.
FT   CONFLICT    144    144       P -> Q (in Ref. 6; CAG47064).
FT                                {ECO:0000305}.
FT   CONFLICT    203    203       L -> S (in Ref. 2; AAC31758).
FT                                {ECO:0000305}.
FT   CONFLICT    215    216       RG -> AR (in Ref. 1; AAA76851).
FT                                {ECO:0000305}.
FT   CONFLICT    296    296       H -> D (in Ref. 1; AAA76851).
FT                                {ECO:0000305}.
FT   CONFLICT    358    358       K -> R (in Ref. 5; BAG35211).
FT                                {ECO:0000305}.
FT   HELIX         7     11       {ECO:0000244|PDB:3B6R}.
FT   HELIX        16     19       {ECO:0000244|PDB:3B6R}.
FT   HELIX        29     33       {ECO:0000244|PDB:3B6R}.
FT   HELIX        36     42       {ECO:0000244|PDB:3B6R}.
FT   HELIX        53     62       {ECO:0000244|PDB:3B6R}.
FT   STRAND       67     69       {ECO:0000244|PDB:3B6R}.
FT   HELIX        81     84       {ECO:0000244|PDB:3B6R}.
FT   HELIX        86     96       {ECO:0000244|PDB:3B6R}.
FT   HELIX       112    114       {ECO:0000244|PDB:3B6R}.
FT   TURN        123    125       {ECO:0000244|PDB:3B6R}.
FT   STRAND      126    135       {ECO:0000244|PDB:3B6R}.
FT   TURN        143    145       {ECO:0000244|PDB:3B6R}.
FT   HELIX       148    162       {ECO:0000244|PDB:3B6R}.
FT   HELIX       167    169       {ECO:0000244|PDB:3B6R}.
FT   STRAND      171    176       {ECO:0000244|PDB:3B6R}.
FT   HELIX       181    189       {ECO:0000244|PDB:3B6R}.
FT   HELIX       200    203       {ECO:0000244|PDB:3B6R}.
FT   TURN        204    214       {ECO:0000244|PDB:3B6R}.
FT   STRAND      216    220       {ECO:0000244|PDB:3B6R}.
FT   STRAND      223    244       {ECO:0000244|PDB:3B6R}.
FT   HELIX       246    266       {ECO:0000244|PDB:3B6R}.
FT   TURN        275    277       {ECO:0000244|PDB:3B6R}.
FT   HELIX       284    286       {ECO:0000244|PDB:3B6R}.
FT   STRAND      292    298       {ECO:0000244|PDB:3B6R}.
FT   HELIX       300    303       {ECO:0000244|PDB:3B6R}.
FT   HELIX       308    314       {ECO:0000244|PDB:3B6R}.
FT   STRAND      317    321       {ECO:0000244|PDB:3B6R}.
FT   HELIX       325    330       {ECO:0000244|PDB:3B6R}.
FT   STRAND      333    338       {ECO:0000244|PDB:3B6R}.
FT   STRAND      342    344       {ECO:0000244|PDB:3B6R}.
FT   HELIX       346    368       {ECO:0000244|PDB:3B6R}.
FT   HELIX       374    376       {ECO:0000244|PDB:3B6R}.
SQ   SEQUENCE   381 AA;  42644 MW;  637AA67A86AE3059 CRC64;
     MPFSNSHNAL KLRFPAEDEF PDLSAHNNHM AKVLTPELYA ELRAKSTPSG FTLDDVIQTG
     VDNPGHPYIM TVGCVAGDEE SYEVFKDLFD PIIEDRHGGY KPSDEHKTDL NPDNLQGGDD
     LDPNYVLSSR VRTGRSIRGF CLPPHCSRGE RRAIEKLAVE ALSSLDGDLA GRYYALKSMT
     EAEQQQLIDD HFLFDKPVSP LLLASGMARD WPDARGIWHN DNKTFLVWVN EEDHLRVISM
     QKGGNMKEVF TRFCTGLTQI ETLFKSKDYE FMWNPHLGYI LTCPSNLGTG LRAGVHIKLP
     NLGKHEKFSE VLKRLRLQKR GTGGVDTAAV GGVFDVSNAD RLGFSEVELV QMVVDGVKLL
     IEMEQRLEQG QAIDDLMPAQ K
//
